Specialty Pharmacy

Brentuximab vedotin (Adcetris) improves survival among patients with anaplastic large cell lymphoma or CD30-expressing mycosis fungoides.

Brentuximab vedotin (Adcetris) improves survival among patients with anaplastic large cell lymphoma or CD30-expressing mycosis fungoides.

Ribociclib (Kisqali) combination therapy may improve survival among premenopausal breast cancer patients.

Secukinumab (Cosentyx) treatment observed to improve the signs and symptoms of psoriatic arthritis.

A comprehensive knowledge of the risk of breast cancer can lead to better screening.

Top news of the day from across the healthcare landscape.

MRI brain scans on children at high risk of multiple sclerosis may indicate earlier diagnoses and treatments.

Joel Wright, chief executive officer, Alliance Rx Walgreens Prime speaks to how medication synchronization programs can improve adherence.

Adalimumab-adbm (Cyltezo) showed equivalent safety and immunogenicity to adalimumab (Humira).

Patients without cirrhosis who achieved a sustained virological response had the lowest risk of hepatocellular carcinoma linked to hepatitis C virus.

It will likely take decades to determine the long-term effects of cannabis, according to a session presented at the American College of Rheumatology Annual Meeting.

Top news of the day from across the healthcare landscape.

Nucala is an interleukin-5 antagonist under consideration as an add-on maintenance therapy for certain patients with chronic obstructive pulmonary disease.

Biosimilars have yet to make a significant impact on the prescription drug market.

FDA officials discuss safety data and drug approvals at the American College of Rheumatology Annual Meeting.

A significant portion of patients with rheumatoid arthritis may develop cardiovascular disease.

With the growing use of cancer immunotherapies, rheumatologists expect to see more cases of inflammatory conditions.

Mortality related to liver cirrhosis outpaces the rate for lung, colorectal, stomach, liver, and breast cancers.

Patients with osteoarthritis may be able to receive targeted therapy based on phenotypes.

Top news of the day from across the healthcare landscape.

Major adverse cardiovascular event rates for baricitinib stabilize over time.

Exercise found to be one of the most important approaches for self-managing the consequences of multiple sclerosis.

Methotrexate discontinuation was not observed to impact rheumatoid arthritis treatment with tocilizumab, according to an abstract presented at the 2017 American College of Rheumatology Annual Meeting.

Alectinib (Alecensa) found to reduce the risk of disease progression in patients with metastatic non-small cell lung cancer.

Sheena Babin, PharmD, business development and clinical pharmacy manager at Ochsner Health System, discusses promising specialty drugs to watch out for in the pipeline.

Amazon entering pharmacy may transform pharmacy benefit managers.

Only 1% of women aged 20 to 68 years had an oral HPV infection.

Officials with the FDA have extended the approval of vemurafenib (Zelboraf, Genentech) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare blood cancer, making it the first approved treatment for ECD.

Some patients with rheumatoid arthritis require a refined treat-to-target plan.

Low incidence of 14-3-3η in patients with long-term RA, chronic HCV with arthralgias.